Big data vs. big trials: can claims records match Gold-Standard results?

NCT ID NCT07599345

First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study uses healthcare claims data from nearly 24,000 people to see if it can reproduce the results of the EMPEROR-Reduced trial, which tested the diabetes drug empagliflozin against sitagliptin in heart failure patients. The goal is not to test a new treatment, but to learn whether real-world data can reliably mimic clinical trials. If it works, it could pave the way for faster, cheaper research using existing health records.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Empagliflozin and sitagliptin
What this could lead to
If successful, this could show that analyzing real-world data can reliably reproduce results from expensive clinical trials, making future research faster and cheaper.
What could go wrong
This is an observational study, not a controlled experiment, so results may be biased or not match the original trial. It only looks at existing records, not new treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02120, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.